## SEC Form 4

 $\square$ 

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	ırden								
hours per responses	0.5								

	Estimated average burden	
	hours per response:	0.5
1		

1. Name and Addres Kammer Rob	ss of Reporting Persor <u>ert J</u>	* )	2. Issuer Name <b>and</b> Ticker or Trading Symbol Imprimis Pharmaceuticals, Inc. [ IMMY ]		tionship of Reporting Person(s) to Issuer all applicable) Director X 10% Owner			
	(First) PHARMACEUTI	, in the second s	3. Date of Earliest Transaction (Month/Day/Year) 04/23/2015		Officer (give title below)		Other (specify below)	
12264 EL CAMINO REAL, SUITE 350			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)				X	ing Person			
SAN DIEGO CA 92130		92130			Form filed by More Person	than C	One Reporting	
(City)	(State)	(Zip)						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially	Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	04/23/2015		М		15,282	Α	\$5.925	988,546	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of E		6. Date Exerc Expiration Da (Month/Day/N	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrant (Right to Buy)	\$5.925	04/23/2015		М			15,282	(1)	04/25/2015	Common Stock	15,282	\$0	0	D	

#### Explanation of Responses:

1. The original warrant, for 48,261 shares of the Issuer's common stock, was issued on April 25, 2012 to DermaStar International, LLC ("DermaStar"), which was dissolved in July 2012. As a member of DermaStar at the time of its dissolution, the portion of the warrant granting the right to acquire 15,282 shares of the Issuer's common stock was distributed by DermaStar to Dr. Kammer on July 12, 2012. The warrant is fully exercisable.

## /s/ Robert J. Kammer

\*\* Signature of Reporting Person

04/27/2015

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.